person · Reporting owner

Popovits Kimberly J

Disclosed activity across 8 companies

Tapewire entity: 36274
SEC CIK: 0001333482

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
10x Genomics, Inc.TXG · Entity 2172	Director	June 04, 2026	June 08, 2026
Kardigan, Inc.KARD · Entity 4569	Director	June 17, 2026	June 22, 2026
Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954	Director	May 29, 2026	June 02, 2026
RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693	Director	April 01, 2026	April 03, 2026
Talis Biomedical CorpTLIS · Entity 87664	Director	June 09, 2023	June 12, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

10x Genomics, Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	37,445	Reported balance After 2026-06-04 transaction · row 1 1 source row Row 1 · 2026-06-04 · Grant · Acquired 8,829 · Balance 37,445 F1: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Filing footnotes · ownership attribution and instrument terms

F1: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Kardigan, Inc.

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,706	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 20,706 · Balance 20,706 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

Kiniksa Pharmaceuticals International, plc

Report date May 29, 2026 · Filed June 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary ShareSEC Table I · non-derivative	Direct	15,345	Reported balance After 2026-05-29 transaction · row 1 1 source row Row 1 · 2026-05-29 · Exercise / conversion · Acquired 2,799 · Balance 15,345 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.38 · Expires 2036-05-28	Direct	12,158	Reported balance After 2026-05-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-29 · Grant · Acquired 12,158 · Balance 12,158 F2: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	2,026	Reported balance After 2026-05-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-29 · Grant · Acquired 2,026 · Balance 2,026 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-29 · Exercise / conversion · Disposed 2,799 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F2: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

F3: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

F4: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

RHYTHM PHARMACEUTICALS, INC.

Report date April 01, 2026 · Filed April 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	6,808	Reported balance After 2026-04-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-01 · Grant · Acquired 6,808 · Balance 6,808 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units will vest as to 33% of the total shares on each of April 1, 2027, April 1, 2028, April 1, 2029. The restricted stock units have no expiration date.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.12 · Expires 2036-03-31	Direct	10,257	Reported balance After 2026-04-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-01 · Grant · Acquired 10,257 · Balance 10,257 F3: The stock options were granted on April 1, 2026. The options vest and become exercisable in three substantially equal annual installments subject to the Reporting Person continuing in service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2: The restricted stock units will vest as to 33% of the total shares on each of April 1, 2027, April 1, 2028, April 1, 2029. The restricted stock units have no expiration date.

F3: The stock options were granted on April 1, 2026. The options vest and become exercisable in three substantially equal annual installments subject to the Reporting Person continuing in service through each such vesting date.

Talis Biomedical Corp

Report date June 09, 2023 · Filed June 12, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-09	Direct	95,000	Reported balance After 2023-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-09 · Grant · Acquired 95,000 · Balance 95,000 F1: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

EXACT SCIENCES CORP

Report date March 23, 2026 · Filed March 23, 2026

Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2026-03-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-03-23 · Disposition to issuer · Disposed 6,725 · Balance 9,656 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). Row 2 · 2026-03-23 · Disposition to issuer · Disposed 9,656 · Balance 0 F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

Filing footnotes · ownership attribution and instrument terms

F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").

F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

GENOMIC HEALTH INC

Report date November 08, 2019 · Filed November 14, 2019

Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHeld by Morgan Stanley as Custodian for Benefit of Kimberly Popovits	0	Reported balance After 2019-11-08 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-11-08 · Disposition to issuer · Disposed 12,298 · Balance 0 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences,Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $338,229 and 5,539 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Common StockSEC Table I · non-derivative	IndirectHeld by the Popovits 2010 Trust	0	Reported balance After 2019-11-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-11-08 · Disposition to issuer · Disposed 68,268 · Balance 0 F2: Disposed of in connection with the Merger, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $1,877,453 and 30,749 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-11-08 transaction · row 3 1 source row Row 3 · 2019-11-08 · Disposition to issuer · Disposed 36,168 · Balance 0 F3: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit ("RSU") was assumed by Exact Sciences and converted into a corresponding award for 27,680 RSUs of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.05 · Expires 2023-01-31	Direct	0	Reported balance After 2019-11-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-08 · Disposition to issuer · Disposed 67,500 · Balance 0 F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $1,077,212, less applicable tax withholdings, and 17,643 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.84 · Expires 2024-01-28	Direct	0	Reported balance After 2019-11-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-08 · Disposition to issuer · Disposed 100,000 · Balance 0 F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $1,481,074, less applicable tax withholdings, and 24,258 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2026-02-16	Direct	12,822	Reported balance After 2019-11-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-08 · Disposition to issuer · Disposed 141,038 · Balance 12,822 F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $2,311,715, less applicable tax withholdings, and 37,864 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2026-02-16	Direct	0	Reported balance After 2019-11-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-08 · Disposition to issuer · Disposed 12,822 · Balance 0 F7: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 9,813 shares of Exact Sciences common stock with an exercise price of $35.28 per share.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.48 · Expires 2027-01-31	Direct	59,844	Reported balance After 2019-11-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-11-08 · Disposition to issuer · Disposed 131,656 · Balance 59,844 F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $2,131,936, less applicable tax withholdings, and 34,919 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.48 · Expires 2027-01-31	Direct	0	Reported balance After 2019-11-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-11-08 · Disposition to issuer · Disposed 59,844 · Balance 0 F9: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 45,800 shares of Exact Sciences common stock with an exercise price of $35.91 per share.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $33.21 · Expires 2028-01-31	Direct	92,869	Reported balance After 2019-11-08 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-11-08 · Disposition to issuer · Disposed 72,231 · Balance 92,869 F10: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $999,359, less applicable tax withholdings, and 16,368 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $33.21 · Expires 2028-01-31	Direct	0	Reported balance After 2019-11-08 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-11-08 · Disposition to issuer · Disposed 92,869 · Balance 0 F11: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 71,075 shares of Exact Sciences common stock with an exercise price of $43.40 per share.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $72.52 · Expires 2029-01-29	Direct	0	Reported balance After 2019-11-08 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-11-08 · Disposition to issuer · Disposed 75,610 · Balance 0 F12: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 57,866 shares of Exact Sciences common stock with an exercise price of $94.76 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences,Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $338,229 and 5,539 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F2: Disposed of in connection with the Merger, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $1,877,453 and 30,749 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F3: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit ("RSU") was assumed by Exact Sciences and converted into a corresponding award for 27,680 RSUs of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $1,077,212, less applicable tax withholdings, and 17,643 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $1,481,074, less applicable tax withholdings, and 24,258 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $2,311,715, less applicable tax withholdings, and 37,864 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F7: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 9,813 shares of Exact Sciences common stock with an exercise price of $35.28 per share.

F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $2,131,936, less applicable tax withholdings, and 34,919 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F9: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 45,800 shares of Exact Sciences common stock with an exercise price of $35.91 per share.

F10: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $999,359, less applicable tax withholdings, and 16,368 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F11: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 71,075 shares of Exact Sciences common stock with an exercise price of $43.40 per share.

F12: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 57,866 shares of Exact Sciences common stock with an exercise price of $94.76 per share.

MyoKardia, Inc.

Report date November 17, 2020 · Filed November 20, 2020

Section 16 reporting ended · disclosed 2020-11-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-11-17 transaction · row 1 1 source row Row 1 · 2020-11-17 · Other · Disposed 4,100 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.35	Direct	Reported balance After 2020-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-17 · Disposition to issuer · Disposed 22,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00	Direct	Reported balance After 2020-11-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.85	Direct	Reported balance After 2020-11-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.77	Direct	Reported balance After 2020-11-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-17 · Disposition to issuer · Disposed 6,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.27	Direct	Reported balance After 2020-11-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-17 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 08, 2019 Filed Aug 12, 2019 19:08 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	15,765	$73.63	$1,160,795.87	Disclosure SEC source: 0001209191-19-045633 · doc4.xml · nonDerivative · entry 3 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 117,703 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on December 10, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $73.03 to $74.02. Read SEC document
August 08, 2019 Filed Aug 12, 2019 19:08 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	Exercise / conversionCommon Stock	25,000	$29.34	$733,500.00	Disclosure SEC source: 0001209191-19-045633 · doc4.xml · nonDerivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 133,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 13, 2019 Filed Jun 17, 2019 22:54 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantRestricted Stock Units · Derivative	2,300	$0.00	$0.00	Disclosure SEC source: 0000899243-19-017222 · doc4.xml · derivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Underlying: Common Stock · 2,300 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 13, 2019 Filed Jun 17, 2019 22:54 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantStock Option (Right to Buy) · Derivative	6,600	$0.00 Strike: $47.17	$0.00	Disclosure SEC source: 0000899243-19-017222 · doc4.xml · derivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,600 Underlying: Common Stock · 6,600 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 13, 2019, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
May 29, 2019 Filed May 30, 2019 22:32 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantShare Option · Derivative	18,760	$0.00 Strike: $15.47	$0.00	Disclosure SEC source: 0001179110-19-006866 · edgar.xml · derivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,760 Underlying: Class A Common Shares · 18,760 shares Expires 2029-05-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is May 29, 2019. Read SEC document
May 29, 2019 Filed Aug 12, 2019 19:08 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	GiftCommon Stock	800	$0.00	$0.00	Disclosure SEC source: 0001209191-19-045633 · doc4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 108,152 Read SEC document
April 08, 2019 Filed Apr 10, 2019 19:45 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	100	$68.31	$6,831.00	Disclosure SEC source: 0001209191-19-024315 · doc4.xml · nonDerivative · entry 4 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 108,952 F5 · price: Represents actual sale price. Read SEC document
April 08, 2019 Filed Apr 10, 2019 19:45 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	2,364	$67.55	$159,676.38	Disclosure SEC source: 0001209191-19-024315 · doc4.xml · nonDerivative · entry 3 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 109,052 F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $67.30 to $68.03. Read SEC document
April 08, 2019 Filed Apr 10, 2019 19:45 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	7,536	$66.72	$502,813.98	Disclosure SEC source: 0001209191-19-024315 · doc4.xml · nonDerivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 111,416 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on December 10, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $66.29 to $67.25. Read SEC document
March 29, 2019 Filed Apr 10, 2019 19:45 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	GiftCommon Stock	7,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-024315 · doc4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 118,952 Read SEC document
March 08, 2019 Filed Mar 12, 2019 21:47 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	847	$73.71	$62,433.56	Disclosure SEC source: 0001209191-19-019046 · doc4.xml · nonDerivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 125,952 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on December 10, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $73.60 to $73.88. Read SEC document
March 08, 2019 Filed Mar 12, 2019 21:47 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	9,153	$73.18	$669,803.73	Disclosure SEC source: 0001209191-19-019046 · doc4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 126,799 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on December 10, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $72.58 to $73.55. Read SEC document
February 15, 2019 Filed Feb 25, 2019 20:12 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	Tax withholdingCommon Stock	12,890	$83.34	$1,074,252.60	Disclosure SEC source: 0001209191-19-013283 · doc4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,138 F1 · balance_after: Includes an aggregate of 36,168 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
February 14, 2019 Filed Feb 19, 2019 19:38 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	47,900	$0.00 Strike: $17.18	$0.00	Disclosure SEC source: 0001209191-19-011362 · doc4.xml · derivative · entry 6 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,900 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter. Read SEC document
February 14, 2019 Filed Feb 19, 2019 19:38 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	13,900	$82.30	$1,143,947.76	Disclosure SEC source: 0001209191-19-011362 · doc4.xml · nonDerivative · entry 3 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 116,982 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 17, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $82.06 to $82.83. Read SEC document
February 14, 2019 Filed Feb 19, 2019 19:38 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	34,000	$81.46	$2,769,667.20	Disclosure SEC source: 0001209191-19-011362 · doc4.xml · nonDerivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 130,882 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 17, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $81.05 to $82.045. Read SEC document
February 14, 2019 Filed Feb 19, 2019 19:38 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	Exercise / conversionCommon Stock	47,900	$17.18	$822,922.00	Disclosure SEC source: 0001209191-19-011362 · doc4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 164,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 29, 2019 Filed Jan 31, 2019 20:23 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	GrantEmployee Stock Option (right to buy) Holding · Derivative	75,610	$0.00 Strike: $72.52	$0.00	Disclosure SEC source: 0001209191-19-006310 · doc4.xml · derivative · entry 4 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,610 Underlying: Common Stock · 0 shares Expires 2029-01-29 F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on January 29, 2020, and becomes exercisable as to 1/48th of the shares each full month thereafter. Read SEC document
January 29, 2019 Filed Jan 31, 2019 20:23 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	GrantCommon Stock	10,960	$0.00	$0.00	Disclosure SEC source: 0001209191-19-006310 · doc4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,028 F1 · shares: Restricted stock units awarded on January 29, 2019 which vest as to 1/3 of the shares on each of February 15, 2020, 2021 and 2022. F2 · balance_after: Includes an aggregate of 51,204 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
December 18, 2018 Filed Dec 19, 2018 17:59 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	3,722	$67.46	$251,101.75	Disclosure SEC source: 0001209191-18-063552 · doc4.xml · nonDerivative · entry 8 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 116,982 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F3 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F10 · price: Represents weighted average sale price. Actual sale prices ranged from $67.16 to $67.87. Read SEC document
December 18, 2018 Filed Dec 19, 2018 17:59 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	17,208	$66.74	$1,148,432.67	Disclosure SEC source: 0001209191-18-063552 · doc4.xml · nonDerivative · entry 7 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 120,704 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F3 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F9 · price: Represents weighted average sale price. Actual sale prices ranged from $66.16 to $67.15. Read SEC document
December 18, 2018 Filed Dec 19, 2018 17:59 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	4,070	$65.79	$267,751.06	Disclosure SEC source: 0001209191-18-063552 · doc4.xml · nonDerivative · entry 6 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 137,912 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F3 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F8 · price: Represents weighted average sale price. Actual sale prices ranged from $65.16 to $66.14. Read SEC document
December 17, 2018 Filed Dec 19, 2018 17:59 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	1,200	$68.53	$82,233.12	Disclosure SEC source: 0001209191-18-063552 · doc4.xml · nonDerivative · entry 5 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 141,982 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F3 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F7 · price: Represents weighted average sale price. Actual sale prices ranged from $68.365 to $68.90. Read SEC document
December 17, 2018 Filed Dec 19, 2018 17:59 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	7,014	$67.89	$476,183.97	Disclosure SEC source: 0001209191-18-063552 · doc4.xml · nonDerivative · entry 4 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 143,182 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F3 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F6 · price: Represents weighted average sale price. Actual sale prices ranged from $67.36 to $68.34. Read SEC document
December 17, 2018 Filed Dec 19, 2018 17:59 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	9,079	$66.78	$606,340.11	Disclosure SEC source: 0001209191-18-063552 · doc4.xml · nonDerivative · entry 3 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 150,196 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F3 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F5 · price: Represents weighted average sale price. Actual sale prices ranged from $66.34 to $67.315. Read SEC document
December 17, 2018 Filed Dec 19, 2018 17:59 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	7,707	$65.85	$507,484.37	Disclosure SEC source: 0001209191-18-063552 · doc4.xml · nonDerivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 159,275 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F3 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $65.32 to $66.30. Read SEC document
November 27, 2018 Filed Dec 19, 2018 17:59 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	GiftCommon Stock	589	$0.00	$0.00	Disclosure SEC source: 0001209191-18-063552 · doc4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,068 F1 · balance_after: Includes an aggregate of 51,204 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
November 16, 2018 Filed Nov 19, 2018 21:27 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	15,000	$0.00 Strike: $22.98	$0.00	Disclosure SEC source: 0001209191-18-059370 · doc4.xml · derivative · entry 14 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter. Read SEC document
November 16, 2018 Filed Nov 19, 2018 21:27 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	1,400	$77.91	$109,067.00	Disclosure SEC source: 0001209191-18-059370 · doc4.xml · nonDerivative · entry 10 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 176,982 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F10 · price: Represents weighted average sale price. Actual sale prices ranged from $77.67 to $78.06. Read SEC document
November 16, 2018 Filed Nov 19, 2018 21:27 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	4,939	$77.10	$380,814.19	Disclosure SEC source: 0001209191-18-059370 · doc4.xml · nonDerivative · entry 9 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 178,382 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F9 · price: Represents weighted average sale price. Actual sale prices ranged from $76.61 to $77.60. Read SEC document
November 16, 2018 Filed Nov 19, 2018 21:27 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	8,661	$76.31	$660,912.25	Disclosure SEC source: 0001209191-18-059370 · doc4.xml · nonDerivative · entry 8 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 183,321 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F8 · price: Represents weighted average sale price. Actual sale prices ranged from $75.60 to $76.58. Read SEC document
November 16, 2018 Filed Nov 19, 2018 21:27 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	Exercise / conversionCommon Stock	15,000	$22.98	$344,700.00	Disclosure SEC source: 0001209191-18-059370 · doc4.xml · nonDerivative · entry 7 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 191,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 16, 2018 Filed Nov 20, 2018 16:45 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	946	$77.93	$73,719.70	Disclosure SEC source: 0001209191-18-059447 · doc4.xml · nonDerivative · entry 4 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 166,982 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F3 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F6 · price: Represents weighted average sale price. Actual sale prices ranged from $77.61 to $78.21. Read SEC document
November 16, 2018 Filed Nov 20, 2018 16:45 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	3,199	$77.11	$246,685.13	Disclosure SEC source: 0001209191-18-059447 · doc4.xml · nonDerivative · entry 3 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 167,928 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F3 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F5 · price: Represents weighted average sale price. Actual sale prices ranged from $76.61 to $77.58. Read SEC document
November 16, 2018 Filed Nov 20, 2018 16:45 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	5,855	$76.31	$446,766.36	Disclosure SEC source: 0001209191-18-059447 · doc4.xml · nonDerivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 171,127 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F3 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $75.61 to $76.59. Read SEC document
November 15, 2018 Filed Nov 19, 2018 21:27 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $22.98	$0.00	Disclosure SEC source: 0001209191-18-059370 · doc4.xml · derivative · entry 13 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 25,000 shares Expires 2021-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter. Read SEC document
November 15, 2018 Filed Nov 19, 2018 21:27 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	10,083	$78.69	$793,389.93	Disclosure SEC source: 0001209191-18-059370 · doc4.xml · nonDerivative · entry 6 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 176,982 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F7 · price: Represents weighted average sale price. Actual sale prices ranged from $78.31 to $79.22. Read SEC document
November 15, 2018 Filed Nov 19, 2018 21:27 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	2,854	$77.56	$221,348.82	Disclosure SEC source: 0001209191-18-059370 · doc4.xml · nonDerivative · entry 5 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 187,065 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F6 · price: Represents weighted average sale price. Actual sale prices ranged from $77.28 to $78.23. Read SEC document
November 15, 2018 Filed Nov 19, 2018 21:27 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	5,138	$76.89	$395,071.61	Disclosure SEC source: 0001209191-18-059370 · doc4.xml · nonDerivative · entry 4 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 189,919 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F5 · price: Represents weighted average sale price. Actual sale prices ranged from $76.27 to $77.22. Read SEC document
November 15, 2018 Filed Nov 19, 2018 21:27 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	1,925	$75.78	$145,879.97	Disclosure SEC source: 0001209191-18-059370 · doc4.xml · nonDerivative · entry 3 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 195,057 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $75.265 to $76.25. Read SEC document
November 15, 2018 Filed Nov 19, 2018 21:27 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	5,000	$74.77	$373,870.00	Disclosure SEC source: 0001209191-18-059370 · doc4.xml · nonDerivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 196,982 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $74.21 to $75.15. Read SEC document
November 15, 2018 Filed Nov 19, 2018 21:27 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	Exercise / conversionCommon Stock	25,000	$22.98	$574,500.00	Disclosure SEC source: 0001209191-18-059370 · doc4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 201,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 16, 2018 Filed Oct 17, 2018 17:52 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $22.98	$0.00	Disclosure SEC source: 0001209191-18-055403 · doc4.xml · derivative · entry 13 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 25,000 shares Expires 2021-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter. Read SEC document
October 16, 2018 Filed Oct 17, 2018 17:52 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	7,885	$67.39	$531,340.19	Disclosure SEC source: 0001209191-18-055403 · doc4.xml · nonDerivative · entry 9 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 176,982 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F9 · price: Represents weighted average sale price. Actual sale prices ranged from $66.97 to $67.73. Read SEC document
October 16, 2018 Filed Oct 17, 2018 17:52 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	8,217	$66.43	$545,836.41	Disclosure SEC source: 0001209191-18-055403 · doc4.xml · nonDerivative · entry 8 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 184,867 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F8 · price: Represents weighted average sale price. Actual sale prices ranged from $65.97 to $66.96. Read SEC document
October 16, 2018 Filed Oct 17, 2018 17:52 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	6,103	$65.41	$399,221.03	Disclosure SEC source: 0001209191-18-055403 · doc4.xml · nonDerivative · entry 7 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 193,084 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F7 · price: Represents weighted average sale price. Actual sale prices ranged from $64.97 to $65.96. Read SEC document
October 16, 2018 Filed Oct 17, 2018 17:52 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	2,795	$64.45	$180,126.85	Disclosure SEC source: 0001209191-18-055403 · doc4.xml · nonDerivative · entry 6 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 199,187 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F6 · price: Represents weighted average sale price. Actual sale prices ranged from $63.97 to $64.96. Read SEC document
October 16, 2018 Filed Oct 17, 2018 17:52 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	Exercise / conversionCommon Stock	25,000	$22.98	$574,500.00	Disclosure SEC source: 0001209191-18-055403 · doc4.xml · nonDerivative · entry 5 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 201,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 15, 2018 Filed Oct 17, 2018 17:52 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $22.98	$0.00	Disclosure SEC source: 0001209191-18-055403 · doc4.xml · derivative · entry 12 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 25,000 shares Expires 2021-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter. Read SEC document
October 15, 2018 Filed Oct 17, 2018 17:52 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	SaleCommon Stock	400	$65.76	$26,304.00	Disclosure SEC source: 0001209191-18-055403 · doc4.xml · nonDerivative · entry 4 Popovits Kimberly J · CIK 0001333482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Popovits 2010 Trust Disclosed balance after: 176,982 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F5 · price: Represents actual sale price. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.